Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine ...
3 Tampilan
• 07/08/23
0
0
Menanamkan
administrator
Pelanggan
Prof Sandip Patel gives a press conference at AACR 2019 on results from the DART phase II trial which showed the combination of ipilimumab and nivolumab to have clinical benefit when treating high-grade neuroendocrine carcinoma.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru